-
The Segment Anything foundation model achieves favorable brain tumor autosegmentation accuracy on MRI to support radiotherapy treatment planning
Authors:
Florian Putz,
Johanna Grigo,
Thomas Weissmann,
Philipp Schubert,
Daniel Hoefler,
Ahmed Gomaa,
Hassen Ben Tkhayat,
Amr Hagag,
Sebastian Lettmaier,
Benjamin Frey,
Udo S. Gaipl,
Luitpold V. Distel,
Sabine Semrau,
Christoph Bert,
Rainer Fietkau,
Yixing Huang
Abstract:
Background: Tumor segmentation in MRI is crucial in radiotherapy (RT) treatment planning for brain tumor patients. Segment anything (SA), a novel promptable foundation model for autosegmentation, has shown high accuracy for multiple segmentation tasks but was not evaluated on medical datasets yet. Methods: SA was evaluated in a point-to-mask task for glioma brain tumor autosegmentation on 16744 tr…
▽ More
Background: Tumor segmentation in MRI is crucial in radiotherapy (RT) treatment planning for brain tumor patients. Segment anything (SA), a novel promptable foundation model for autosegmentation, has shown high accuracy for multiple segmentation tasks but was not evaluated on medical datasets yet. Methods: SA was evaluated in a point-to-mask task for glioma brain tumor autosegmentation on 16744 transversal slices from 369 MRI datasets (BraTS 2020). Up to 9 point prompts were placed per slice. Tumor core (enhancing tumor + necrotic core) was segmented on contrast-enhanced T1w sequences. Out of the 3 masks predicted by SA, accuracy was evaluated for the mask with the highest calculated IoU (oracle mask) and with highest model predicted IoU (suggested mask). In addition to assessing SA on whole MRI slices, SA was also evaluated on images cropped to the tumor (max. 3D extent + 2 cm). Results: Mean best IoU (mbIoU) using oracle mask on full MRI slices was 0.762 (IQR 0.713-0.917). Best 2D mask was achieved after a mean of 6.6 point prompts (IQR 5-9). Segmentation accuracy was significantly better for high- compared to low-grade glioma cases (mbIoU 0.789 vs. 0.668). Accuracy was worse using MRI slices cropped to the tumor (mbIoU 0.759) and was much worse using suggested mask (full slices 0.572). For all experiments, accuracy was low on peripheral slices with few tumor voxels (mbIoU, <300: 0.537 vs. >=300: 0.841). Stacking best oracle segmentations from full axial MRI slices, mean 3D DSC for tumor core was 0.872, which was improved to 0.919 by combining axial, sagittal and coronal masks. Conclusions: The Segment Anything foundation model, while trained on photos, can achieve high zero-shot accuracy for glioma brain tumor segmentation on MRI slices. The results suggest that Segment Anything can accelerate and facilitate RT treatment planning, when properly integrated in a clinical application.
△ Less
Submitted 16 April, 2023;
originally announced April 2023.
-
Deep learning for automatic head and neck lymph node level delineation provides expert-level accuracy
Authors:
Thomas Weissmann,
Yixing Huang,
Stefan Fischer,
Johannes Roesch,
Sina Mansoorian,
Horacio Ayala Gaona,
Antoniu-Oreste Gostian,
Markus Hecht,
Sebastian Lettmaier,
Lisa Deloch,
Benjamin Frey,
Udo S. Gaipl,
Luitpold V. Distel,
Andreas Maier,
Heinrich Iro,
Sabine Semrau,
Christoph Bert,
Rainer Fietkau,
Florian Putz
Abstract:
Background: Deep learning (DL)-based head and neck lymph node level (HN_LNL) autodelineation is of high relevance to radiotherapy research and clinical treatment planning but still underinvestigated in academic literature. Methods: An expert-delineated cohort of 35 planning CTs was used for training of an nnU-net 3D-fullres/2D-ensemble model for autosegmentation of 20 different HN_LNL. A second co…
▽ More
Background: Deep learning (DL)-based head and neck lymph node level (HN_LNL) autodelineation is of high relevance to radiotherapy research and clinical treatment planning but still underinvestigated in academic literature. Methods: An expert-delineated cohort of 35 planning CTs was used for training of an nnU-net 3D-fullres/2D-ensemble model for autosegmentation of 20 different HN_LNL. A second cohort acquired at the same institution later in time served as the test set (n=20). In a completely blinded evaluation, 3 clinical experts rated the quality of DL autosegmentations in a head-to-head comparison with expert-created contours. For a subgroup of 10 cases, intraobserver variability was compared to the average DL autosegmentation accuracy on the original and recontoured set of expert segmentations. A postprocessing step to adjust craniocaudal boundaries of level autosegmentations to the CT slice plane was introduced and the effect on geometric accuracy and expert rating was investigated. Results: Blinded expert ratings for DL segmentations and expert-created contours were not significantly different. DL segmentations with slice plane adjustment were rated numerically higher (mean, 81.0 vs. 79.6,p=0.185) and DL segmentations without slice plane adjustment were rated numerically lower (77.2 vs. 79.6,p=0.167) than manually drawn contours. DL segmentations with CT slice plane adjustment were rated significantly better than DL contours without slice plane adjustment (81.0 vs. 77.2,p=0.004). Geometric accuracy of DL segmentations was not different from intraobserver variability (mean, 0.76 vs. 0.77, p=0.307). Conclusions: We show that a nnU-net 3D-fullres/2D-ensemble model can be used for highly accurate autodelineation of HN_LNL using only a limited training dataset that is ideally suited for large-scale standardized autodelineation of HN_LNL in the research setting.
△ Less
Submitted 1 March, 2023; v1 submitted 28 August, 2022;
originally announced August 2022.
-
Deep learning for brain metastasis detection and segmentation in longitudinal MRI data
Authors:
Yixing Huang,
Christoph Bert,
Philipp Sommer,
Benjamin Frey,
Udo Gaipl,
Luitpold V. Distel,
Thomas Weissmann,
Michael Uder,
Manuel A. Schmidt,
Arnd Dörfler,
Andreas Maier,
Rainer Fietkau,
Florian Putz
Abstract:
Brain metastases occur frequently in patients with metastatic cancer. Early and accurate detection of brain metastases is very essential for treatment planning and prognosis in radiation therapy. To improve brain metastasis detection performance with deep learning, a custom detection loss called volume-level sensitivity-specificity (VSS) is proposed, which rates individual metastasis detection sen…
▽ More
Brain metastases occur frequently in patients with metastatic cancer. Early and accurate detection of brain metastases is very essential for treatment planning and prognosis in radiation therapy. To improve brain metastasis detection performance with deep learning, a custom detection loss called volume-level sensitivity-specificity (VSS) is proposed, which rates individual metastasis detection sensitivity and specificity in (sub-)volume levels. As sensitivity and precision are always a trade-off in a metastasis level, either a high sensitivity or a high precision can be achieved by adjusting the weights in the VSS loss without decline in dice score coefficient for segmented metastases. To reduce metastasis-like structures being detected as false positive metastases, a temporal prior volume is proposed as an additional input of DeepMedic. The modified network is called DeepMedic+ for distinction. Our proposed VSS loss improves the sensitivity of brain metastasis detection for DeepMedic, increasing the sensitivity from 85.3% to 97.5%. Alternatively, it improves the precision from 69.1% to 98.7%. Comparing DeepMedic+ with DeepMedic with the same VSS loss, 44.4% of the false positive metastases are reduced in the high sensitivity model and the precision reaches 99.6% for the high specificity model. The mean dice coefficient for all metastases is about 0.81. With the ensemble of the high sensitivity and high specificity models, on average only 1.5 false positive metastases per patient needs further check, while the majority of true positive metastases are confirmed. The ensemble learning is able to distinguish high confidence true positive metastases from metastases candidates that require special expert review or further follow-up, being particularly well-fit to the requirements of expert support in real clinical practice.
△ Less
Submitted 16 September, 2022; v1 submitted 22 December, 2021;
originally announced December 2021.
